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Abstract 
Klingeborn, M. 2006. The Prion Protein in Normal Cells and Disease - Studies on the 
Cellular Processing of Bovine PrP
C and Molecular Characterization of the Nor98 Prion. 
Doctoral thesis. 
ISSN 1652-6880, ISBN 91-576-7254-7 
 
Transmissible spongiform encephalopathies (TSEs) are also known as prion diseases. The 
unusual infectious agent is composed largely, if not entirely, of a proteinase resistant 
aberrantly folded isoform of the prion protein (PrP
Sc). PrP
Sc, through an unknown 
mechanism, is believed to impose its aberrant conformation onto the host-encoded cellular 
prion protein, PrP
C. The infectious particle is designated a “prion”, an acronym for 
proteinaceous infectious particle, to distinguish it from conventional pathogens such as 
viruses and bacteria. 
 
The essential role of PrP
C in the pathogenesis of prion diseases motivated the detailed 
study of the cellular processing, turnover and release of bovine PrP
C (boPrP
C) performed in 
this thesis. BoPrP
C was found to be subjected to two distinct proteolytic cleavage events, 
generating an N-terminal and a C-terminal boPrP
C fragment. Both PrP fragments were 
released from the cell. Moreover, in normal bovine brain a C-terminal fragment was found, 
suggesting that similar proteolytic processing events occur in vivo. 
 
The finding that boPrP
C in addition to a protease-mediated release also was released in 
association with exosomes, provide important information in relation to functional aspects 
of PrP
C and possible roles of exosome-associated PrP in pathogenesis of prion diseases. 
Taken together, these results indicate that release of boPrP
C from cells represent an 
important step in the normal cellular processing of boPrP
C. 
 
Nor98 is a recently recognised prion disease in sheep. The molecular characterization of the 
Nor98 prion showed that the unique PK-resistant PrP fragments present in Nor98-affected 
sheep display striking similarities to those reported from individuals affected by the human 
prion disorder Gerstmann-Sträussler-Scheinker syndrome (GSS). Interestingly, GSS is 
always associated with amino acid substitutions in the PrP. Differently, no disease-causing 
changes in the PrP of Nor98-affected sheep have been found in the affected sheep in 
Sweden. These findings together with observations of a distinct epidemiology, suggest that 
Nor98 could be the result of a spontaneous conversion of PrP
C into PrP
Sc, similar to that 
proposed for sporadic Creutzfeldt-Jakob disease and sporadic fatal insomnia. 
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Abbreviations 
a a         a m i n o   a c i d  
boPrP        bovine  PrP 
BSE       Bovine  Spongiform  Encephalopathy  (mad  cow  disease) 
CJD       Creutzfeldt-Jakob  disease 
huPrP        human  PrP 
moPrP      mouse  PrP   
GPI         glycosylphosphatidylinositol 
GSS       Gerstmann-Sträussler-Scheinker  syndrome 
ORF        open  reading  frame   
ovPrP        ovine  PrP 
PIPLC      phosphatidylinositol-specific  phospholipase  C 
PK         proteinase  K   
PNGase  F      peptide:  N-glycosidase  F 
PRNP/Prnp     PrP  gene 
PrP         prion  protein 
PrP
C       cellular  prion  protein 
PrP
Nor98       PK-resistant Nor98 disease-associated isoform of PrP 
PrP-res       PK-resistant  PrP 
PrP
Sc        PK-resistant  disease-associated  isoform  of  PrP         
PrP*  the infectious entity in prions, a hypothetical abnormal isoform 
of PrP, different from both PrP
C and PrP
Sc 
PrP  27-30  PK-resistant core of PrP
Sc resulting from exogenous PK-
treatment 
rPrP       recombinantly  expressed  PrP   
SHaPrP       Syrian  hamster  PrP 
TSE       Transmissible  Spongiform  Encephalopathy 
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Background 
One of the more significant paradigm shifts in molecular medicine during the last 
25 years was the move away from the clinical-neuropathologic classification of 
scrapie and Creutzfeldt-Jakob disease (CJD) as ‘‘transmissible spongiform 
encephalopathies’’ (TSEs) to the recognition of the central causal and pathogenic 
roles played by the prion protein (PrP) and classification of these and related 
neurodegenerative disorders as “prion diseases” (Prusiner et al., 1998). The animal 
syndromes include scrapie of sheep, bovine spongiform encephalopathy (BSE), 
chronic wasting disease of mule deer and elk (CWD), transmissible mink 
encephalopathy, and feline spongiform encephalopathy. Recently also atypical 
variants of prion diseases in animals such as Nor98 in sheep and BASE in cattle, 
have been discovered, possibly representing a group of sporadic prion diseases in 
animals (Benestad et al., 2003; Casalone et al., 2004; Watts, Balachandran & 
Westaway, 2006). The list of human prion diseases includes sporadic, familial, 
iatrogenic, and variant CJD (sCJD, fCJD, iCJD, and vCJD, respectively); 
Gerstmann-Sträussler-Scheinker syndrome (GSS); sporadic and familial fatal 
insomnia (sFI and FFI, respectively); and kuru. In the past, these diseases were 
thought to be caused by ‘‘slow viruses’’ because the ‘‘infectious’’ agents that 
transmit these diseases are possible to filter and incubation times are typically 
months to years. Several unconventional properties regarding the transmissible 
agent, such as resistance to high temperature (Brown et al., 2000b; Gordon, 1946), 
high pressures (Brown et al., 2003), formaldehyde treatment (Gordon, 1946), and 
UV-radiation (Alper et al., 1967; Alper, Haig & Clarke, 1966; Gibbs, Gajdusek & 
Latarjet, 1978; Latarjet et al., 1970) added to the obscurity of these diseases 
(Prusiner, 1982; Prusiner, 1998). The etiology remained perplexing, because 
approximately 99% of human prion diseases cannot be connected to infection and 
the histological features are dissimilar to those of a typical infectious process. An 
additionally puzzling characteristic is that 10% to 15% of human prion diseases 
are dominantly inherited, including all cases of GSS, all cases of FFI, and 
approximately 10% of CJD cases (fCJD). There was no precedent to explain how a 
disease could be both infectious and genetic. 
 
The molecular mechanisms fundamental to such contradictory associations in 
prion diseases have been revealed over the past two decades, beginning with the 
discovery that the ‘‘infectious’’ agent that transmits scrapie is composed largely, if 
not entirely, of a protease-resistant, 27-kDa to 30-kDa protein (Prusiner, 1982). 
The infectious particle was designated a ‘‘prion’’, an acronym for proteinaceous 
infectious particle, to distinguish it from conventional pathogens such as viruses 
and bacteria. The polypeptide constituting the proteinase K (PK)-treated prion 
particle was designated PrP 27-30. This was followed by the discovery that PrP is 
encoded by a single copy mammalian gene, designated PRNP in humans, sheep, 
and cattle and Prnp in mice and hamsters (Oesch et al., 1985). In humans, the 
PRNP gene is located on chromosome 20, in mice on chromosome 2 (Sparkes et 
al., 1986) and, in cattle and sheep on chromosome 13 (Iannuzzi et al., 1998). PrP 
27-30 was found to be derived from a larger 30-kDa to 35-kDa protein, designated 
PrP
Sc(rapie), in scrapie-infected animals, and PrP
Sc was found to be derived from a  10
normal constitutively expressed protease-sensitive PrP isoform, designated PrP
C 
(Meyer et al., 1986). Subsequently, all of the dominantly inherited forms of prion 
disease were genetically linked to mutations of, or insertions in, the PRNP gene 
(DeArmond & Prusiner, 1996; Gambetti & Parchi, 1999; Hsiao et al., 1989).  
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Introduction 
How can a protein have the characteristics of a conventional contagious agent? 
Evidence from many laboratories indicates that the mature, full-length PrP 
molecule can exist in at least two conformations without additional chemical 
modifications: a normal, nonpathogenic isoform that is largely -helical with little 
-sheet content, characteristic of the constitutively expressed normal cellular 
conformer (PrP
C); and an abnormal, pathogenic isoform with less -helical and 
more  -sheet content, characteristic of the disease-associated isoform (PrP
Sc). 
Furthermore, PrP
Sc can interact with the PrP
C expressed by mammalian cells and 
cause the PrP
C to take on an identical -sheet conformation, which starts off a self-
perpetuating process that results in increasing PrP
Sc concentrations and prion 
infectivity titres (Prusiner, et al., 1998). That a protein can have the ability to adopt 
two conformations without chemical modification is not a feature restricted to PrP. 
For example, several other proteins involved in the pathogenesis of diseases called 
“protein misfolding disorders” (PMDs) have also been shown to display this 
property under certain circumstances, for a review see (Soto, Estrada & Castilla, 
2006).  Furthermore, the prion concept has been extended to explain three unusual 
genetic elements of the yeast Saccharomyces cerevisiae and one of the filamentous 
fungus  Podospora anserina. The three yeast proteins - the nitrogen regulatory 
protein Ure2p, the ribosome termination factor Sup35, a nonessential protein of 
unknown function denoted Rnq1, and the Het-s protein in P. anserina - have 
prion-like characteristics: like prions, they can undergo conformational changes, 
acquire  -sheet structure, and selfaggregate into intracellular, -rich, protease-
resistant agglomerate (Uptain & Lindquist, 2002).  
 
From studies of mammalian and yeast prions four new concepts have 
crystallised (Prusiner, 2001; Weissmann, 2004). First, the only known pathogens 
that are devoid of nucleic acids are prions. All other infectious agents possess 
genomes that direct the synthesis of their progeny. Second, like other 
neurodegenerative disorders, prion diseases can manifest as either sporadic or 
genetic diseases. Unlike other neurodegenerative disorders, however, prion 
diseases can be infectious – infectious prions are formed irrespective of the 
initiating molecular event. Third, neurodegeneration in prion diseases results from 
the accumulation of PrP
Sc or some abnormal conformer of PrP
C, and PrP
Sc is 
almost invariably detected in prion-infected tissues and cells, which because of its 
high  -sheet content, is relatively resistant to degradation by cells, including 
neurons (DeArmond & Bouzamondo, 2002). Fourth, PrP
Sc can take on a range of 
pathogenic conformations that give prions the strain features associated with 
different disease phenotypes (Telling et al., 1996). 
 
The protein-only hypothesis 
The extraordinary resistance of prions to radiation (Alper, et al., 1967; Alper, Haig 
& Clarke, 1966) led early on to the suggestion that they might be lacking nucleic 
acid and consist only of protein (Griffith, 1967). The “protein-only” hypothesis as 
stated by Stanley Prusiner proposes that the prion is a proteinaceous infectious  12
particle that lacks nucleic acid and that the infectious, abnormal conformer of PrP
C 
is propagated autocatalytically (Prusiner, 1982; Prusiner, 1997; Prusiner, 1998). 
Models for the specific mechanism of prion propagation is discussed in detail 
below (Propagation of PrP
Sc). It is, however, not clear if the infectious entity is 
composed of PrP
Sc or PrP* (an abnormal conformer of PrP
C different from PrP
Sc). 
The presence of a small ligand in addition to PrP
Sc/PrP* in the prion particle, 
cannot be completely excluded. 
 
There are a number of lines of evidence that supports the protein-only hypothesis 
(modified from (Prusiner, 1998; Soto, Estrada & Castilla, 2006)): 
 
•  PrP
Sc and scrapie infectivity co-purify when biochemical and 
immunologic procedures are used. That is, highly purified preparations of 
PrP
Sc transmit the disease (Prusiner et al., 1984).  
•  Procedures that inactivate PrP
Sc markedly reduce or eliminate infectivity 
(Prusiner et al., 1993).  
•  Levels of PrP
Sc are directly proportional to prion titers. Non-denatured 
PrP
Sc has not been separated from scrapie infectivity (Gabizon et al., 
1988). 
•  No evidence exists for a virus-like particle or a nucleic acid genome 
(Safar et al., 2005). The infectious agent is not affected by procedures 
that normally destroy nucleic acids (Alper, et al., 1967; Prusiner, 1982).  
•  Accumulation of PrP
Sc is almost invariably associated with the pathology 
of prion diseases, including PrP amyloid plaques that are pathognomonic.  
•  PrP gene mutations are genetically linked to inherited prion disease and 
cause formation of PrP
Sc.  
•  PrP gene knockout mice are not susceptible to prion infection. As the 
substrate necessary for PrP
Sc formation have been eliminated both prion 
disease and prion replication is prevented (Bueler et al., 1993). In 
addition, overexpression of PrP
C increases the rate of PrP
Sc formation, 
which shortens the incubation time. 
•  Species variations in the PrP sequence are responsible, at least in part, for 
the species barrier that is found when prions are passaged from one host 
to another.  
•  Chimeric and partially deleted PrP genes change susceptibility to prions 
from different species and support production of artificial prions with 
novel properties that are not found in nature (Legname et al., 2004; 
Legname et al., 2005).  
•  Prion diversity is enciphered within the conformation of PrP
Sc. Strains 
can be generated by passage through hosts with different PrP genes.  
•  Accumulation of PrP
Sc in FFI distinct from that found in fCJD with the 
same D178N mutation, suggest distinct prion strains with diverse 
pathological potential (Montagna et al., 2003). 
•  PrP
Sc can induce the conversion of PrP
C  in vitro in an autocatalytic 
fashion (Caughey et al., 1999; Kocisko et al., 1994; Saborio, Permanne & 
Soto, 2001).  
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In addition, even though not yet achieved completely in mammalian systems, the 
protein-only hypothesis has been demonstrated to be valid with the use of yeast 
prions (see below under Prion Strains and (King & Diaz-Avalos, 2004; Sparrer et 
al., 2000; Tanaka et al., 2004; Tanaka et al., 2006)), albeit not as much bona fide 
prion proteins as proteins with prion-like properties. 
 
Even though many lines of evidence support the protein-only hypothesis, 
alternative models have been suggested for the composition of the TSE agent and 
the pathogenesis of TSEs (Chesebro, 1999; Kimberlin, 1982; Manuelidis, 2003; 
Weissmann, 1991). All of these alternative models predicates in one way or 
another that a TSE-specific nucleic acid is crucial for prion propagation and/or 
modulating strain-specific characteristics of the TSE agent. However, the failure to 
identify a TSE-associated nucleic acid in spite of intense efforts in many 
laboratories have led to that these models have lost much support (Safar, et al., 
2005; Weissmann, 2004). 
 
Prion diseases 
Some of the distinctive features of TSEs or prion diseases are neuronal vacuolation 
(spongiosis), neuronal death, and explicit glial reactions. In addition, a defining 
characteristic is the deposition, mainly in the brain and lymphoreticular tissues, of 
PrP
Sc. Also, no adaptive immune responses are elicited upon infection, most likely 
because the mammalian immune system is largely tolerant to PrP of the same 
species. This is not surprising, given that many cells in neural and extraneural 
compartments express PrP
C. Although TSEs are by definition transmissible, a 
growing number of Prnp-associated non-infectious neurodegenerative 
proteinopathies are now also being recognized (Chiesa et al., 2003; Tateishi & 
Kitamoto, 1995; Weissmann & Flechsig, 2003).  
 
Scrapie - the prototype prion disease 
Scrapie, the prototypic prion disease affecting sheep and goats has been recog-
nized in sheep and goat populations for more than two centuries making it the old-
est described member of the TSEs (Stockman, 1913). An important breakthrough 
was the experimental transmission of scrapie to goats reported in 1939 (Cuille & 
Chelle, 1939). Scrapie is considered to occur worldwide with a small number of 
exceptions. Australia and New Zealand eradicated scrapie following its in-
troduction in imported sheep and are now regarded as being free of scrapie. A 
prominent characteristic of scrapie is pruritus, hence the name of the disease. 
Sheep that are affected sometimes rub against solid objects to the point where 
wool is scraped off (Williams, 2003). 
 
Extensive retrospective studies together with a review of world literature led to 
the conclusion, published in 1987, that scrapie had never passed to humans despite 
opportunities to do so over the 250 years during which the disease had con-
taminated sheepmeat entering the human food chain (Brown et al., 1987). It was 
also recently reported that Gombojav and co-workers (Gombojav et al., 2003) 
failed to infect Hu/Mo chimeric transgenic mice with either sheep or mouse- 14
adapted scrapie, further supporting the above view. Gajdusek and colleagues also 
reported difficulties infecting chimpanzees with sheep scrapie (Gibbs & Gajdusek, 
1973). 
 
Scrapie is a very rare disese in Sweden, in fact the only documented cases were 
diagnosed in 1986 in two ewes from the same flock (Elvander, Engvall & 
Klingeborn, 1988). The diagnosis was based on clinical history and patho-
anatomical changes only and to verify the diagnosis, inoculations into C57/Bl mice 
and Swedish landrace goats were performed. Mice started exhibiting symptoms of 
scrapie 13 months post inoculation (p.i.) and histopathological examination 
revealed typical signs of scrapie. Goats started showing signs of scrapie 16 months 
p.i. Typical signs of scrapie, such as vacuolisation and spongiform degeneration, 
were seen also in goats upon histopathological examination. These inoculation 
experiments confirmed that these sheep were indeed affected by scrapie. Western 
immunoblotting performed recently on brain homogenates from one of these 
affected sheep also showed that the molecular characteristics displayed by the 
PrP
Sc are those of classical scrapie (Klingeborn et al., 2006b). 
  
Susceptibility alleles in scrapie 
Common polymorphisms at codons 136 (V or A), 154 (H or R) and 171 (R or Q) 
of the ovPrP define alleles (represented by the single letter amino-acid code in the 
order 136:154:171) that are linked to survival time of sheep exposed to natural 
scrapie or experimental scrapie and BSE (Belt et al., 1995; Bossers et al., 1997; 
Bossers, de Vries & Smits, 2000; Bossers, Harders & Smits, 1999; Bossers et al., 
1996; Goldmann et al., 1994; Hunter et al., 1996). The relative resistance to 
classical scrapie infection in sheep carrying the five most common ovPrP alleles 
are ARR>AHQ>ARH>ARQ>VRQ.  
 
Cell-free conversion of PrP
C offer an in vitro model, in which relative amounts 
of formed proteinase K (PK)-resistant PrP mirror important biological features of 
TSEs at the molecular level (Bossers, et al., 1997; Bossers, de Vries & Smits, 
2000; Bossers, Harders & Smits, 1999; Bossers et al., 2003; Caughey et al., 1995; 
Raymond et al., 1997). This method has shown that V136- and wt-PrP
C (i.e. A136-
PrP
C) are readily converted into PrP-res by a range of types of PrP
Sc isolated from 
sheep having different PrP genotypes. In contrast, R171-PrP is hardly converted 
into PrP-res (Bossers, et al., 1997; Bossers, de Vries & Smits, 2000; Bossers, 
Harders & Smits, 1999; Bossers, et al., 2003; Raymond et al., 2000). These 
observations demonstrate that the conversion efficiencies of distinct ovPrP
C allelic 
variants into a PK-resistant isoform can be directly correlated to the level of 
susceptibility to scrapie in vivo. 
 
BSE and vCJD 
The BSE epidemic in the UK has caused more than 180,000 cases since 1986 and 
the total number of infected animals have been estimated at around one million 
(Collinge, 2001). A range of exotic zoo animals of the felidae and bovidae families 
were also infected through the consumption of BSE-contaminated bovine meat 
products (Cunningham et al., 2004; Sigurdson & Miller, 2003) and data strongly   15
support a link between BSE and variant Creutzfeldt-Jakob disease (vCJD) in 
humans (Bruce et al., 1997; Collinge, 1999; Hill et al., 1997; Scott et al., 1999). 
Transmission of bovine prions across the bovine-human species barrier could be 
due to either a genetic disposition of the human prion protein (Tabrizi, Elliott & 
Weissmann, 2003) or an intrinsic property of the bovine prion protein and its 
metabolism (Collinge, 1999), or both.  
 
In response to the discovery that the BSE prion probably had infected humans a 
committee was formed, The BSE Inquiry, which was given the task to establish 
and review the history of the emergence and identification of BSE and variant CJD 
in the United Kingdom, and of the action taken in response to it up to 20 March 
1996 (http://www.bseinquiry.gov.uk/). Many important findings were disclosed in 
the BSE Inquiry report, and some of the most important were (Matravers, 
Bridgeman & Ferguson-Smith, 2000): 
 
• The cases of BSE identified between 1986 and 1988 were not index cases, nor 
were they the result of the transmission of scrapie. They were the consequences of 
recycling of cattle infected with BSE itself. The BSE agent was spread in meat-
and-bone meal (MBM).  
 
• BSE probably originated from a novel source early in the 1970s, possibly a cow 
or other animal that developed disease as a consequence of a gene mutation or a 
spontaneous conformational change of PrP (Scott et al., 2005). The origin of the 
disease will probably never be known with certainty.  
 
• Rendering methods have never been capable of completely inactivating TSE 
agents. However, changes in rendering methods in the mid to late 1970’s might 
possibly have resulted in a larger fraction of BSE prions to survive in the MBM 
fed to cattle, although experimental data is inconclusive in this regard.  
 
The incidence of vCJD in the UK increased each year from 1996 to 2001 
(www.dh.gov.uk and www.cjd.ed.ac.uk), eliciting fears of a large upcoming 
epidemic. Since then, however, the incidence of vCJD in the UK seems to be 
stabilizing and may in fact even be falling. Consequently, there is considerable 
hope that the total number of vCJD victims will be fairly small even though 
concerns over longer incubation times in individuals carrying certain 
polymorphisms in the PrP gene have been raised (Collinge et al., 2006; Valleron et 
al., 2006; Valleron et al., 2001). A polymorphism at position 129 in huPrP have 
been shown to influence the incubation period and phenotype in iCJD and kuru 
(Brown et al., 2000a; Collinge, et al., 2006). All vCJD cases diagnosed to date 
have been homozygous for the M129 allele except one heterozygote infected via 
blood-borne transmission (Hewitt et al., 2006). Consequently, cases expressing 
MV129 or VV129 may be identified in the future, and it is possible that these may 
present with a different clinicopathologic phenotype compared with the cases seen 
to date. In addition, the recent discovery of transmission of vCJD via blood in 
three individuals has stirred up worries that blood-borne prion transmission, in 
combination with an unknown prevalence of vCJD-infected carriers, may lead to 
secondary transmission of host-adapted prions (Hewitt, et al., 2006; Peden et al.,  16
2004). This could possibly result in a lengthening of the vCJD epidemic or, in the 
worst-case scenario, may cause vCJD to become endemic and self-sustained. 
 
Since the BSE prion is distinct from all other prions known to date, except for 
the vCJD prion which it is casually linked to, an interesting question is raised: Was 
a particular conformation of bovine PrP
Sc selected for heat resistance during the 
rendering process and then reselected multiple times as cattle infected by ingesting 
prion-contaminated MBM were slaughtered and their offal rendered into more 
MBM? In this regard it is interesting to note that some atypical cases of prion 
disease have recently been dicovered in cattle (Baron & Biacabe, 2006; Baron et 
al., 2006; Biacabe et al., 2004; Buschmann et al., 2004; Casalone, et al., 2004). 
Could any of these possibly sporadic/spontaneous TSEs in cattle be the origin of 
the BSE prion? Future investigations will hopefully answer these questions. 
 
Nor98 
A number of atypical cases of scrapie were diagnosed in sheep in Norway for the 
first time in 1998 and subsequently designated Nor98 (Benestad, et al., 2003). 
Similar atypical scrapie cases were also reported from other parts of Europe (De 
Bosschere et al., 2004; Everest et al., 2006; Onnasch et al., 2004)  including 
Sweden (Gavier-Widen et al., 2004). Nor98 cases differ from classical scrapie and 
BSE in several features, including the pattern of PrP
Sc deposits and the 
neuroanatomical distribution of the histopathological lesions in the brain 
(Benestad, et al., 2003). Other uncommon features are observed in the clinical 
presentation, epidemiology, and frequency of genotypes of sheep affected 
(Benestad, et al., 2003; Gavier-Widen, et al., 2004; Klingeborn, et al., 2006b; 
Moum et al., 2005). The differentiation between classical scrapie and Nor98 is 
based on these features and substantiated by the observation of the Nor98 western 
blot electrophoretic profile, typified by a fast migrating PK-resistant fragment 
(Benestad, et al., 2003; Klingeborn, et al., 2006b). PK-treated brain extracts from 
Nor98 cases demonstrate PrP fragments of sizes similar to full-length as well as a 
smaller fragment migrating to around 7 kDa (Klingeborn, et al., 2006b). The 
smallest fragment seen in classical scrapie extracts is a C-terminal, PK-resistant 
peptide of around 19-21 kDa (Hayashi et al., 2005; Hope et al., 1999; Stahl et al., 
1993). However, brain extracts from subjects affected by certain types of 
Gerstmann-Sträussler-Scheinker disease (GSS) contain PrP-res fragments of 
around 11 to 7 kDa carrying ragged N- and C-termini (Ghetti et al., 1996; Parchi et 
al., 1998; Piccardo et al., 1995; Piccardo et al., 2001; Piccardo et al., 1996; 
Tagliavini et al., 2001; Tagliavini et al., 1991). GSS is a prion disease with a 
genetic background with various mutations in the open reading frame of the prion 
protein gene (for a review see (Young et al., 1999)).  
 
Differently, in Nor98-affected sheep no mutations in the structural gene of PrP 
that can be correlated to the aberrant PK-resistant profile have been observed 
(Klingeborn, et al., 2006b; Moum, et al., 2005). Moum et al. recently sequenced 
the open reading frame (ORF) of PRNP in 38 Norwegian cases of Nor98 and an 
association with polymorphisms at codons 141 and 154 (ovine numbering) was 
found (Moum, et al., 2005). In this aspect, the first six cases found in Sweden   17
(2003-2005) were homozygous for leucine at position 141 and did not display the 
association found in Norway. However, the genotype distribution at codons 136, 
154 and 171 in five of the six cases resembled the pattern found among Nor98 
cases in Norway in that ARQ and/or AHQ is always present while VRQ is 
missing. However, one case carried the A136R154R171/A136R154H171 genotype 
(Klingeborn, et al., 2006b). The widespread geographical distribution, single cases 
in each affected flock and the lack of genetic evidence suggests that Nor98 could 
possibly be a spontaneous/sporadic prion disease. In this regard it is noteworthy 
that similar to the Nor98/GSS comparison, sporadic fatal insomnia (sFI) show all 
the hallmarks of familial fatal insomnia (FFI) but lack the D178N substitution that 
is always associated with FFI (Mastrianni et al., 1999; Montagna, et al., 2003; Pan 
et al., 2001; Parchi et al., 1999; Piao et al., 2005; Scaravilli et al., 2000; Watts, 
Balachandran & Westaway, 2006). 
 
The likelihood that Nor98 cases were not genuine TSEs was excluded by the 
transmission of ten French atypical isolates and three Norwegian Nor98 cases to 
transgenic mice overexpressing ovine PrP (V136R154Q171)(Le Dur et al., 2005). 
 
It is interesting to note that Nor98 affect sheep carrying genotypes which are 
considered to confer a relatively high or high resistance to scrapie infection 
(Benestad, et al., 2003; Gavier-Widen, et al., 2004; Klingeborn, et al., 2006b; 
Moum, et al., 2005).This would suggest that ARR/ARR sheep can no longer be 
considered as free of natural TSE infection. Furthemore, this finding puts serious 
strain on, at least to some extent, the foundation of the selective breeding programs 
implemented in several European Union member states (Anonymous, 1999; 
Anonymous, 2006; Arnold et al., 2002; Baylis & McIntyre, 2004) and may call for 
a reassessment of consequences of this guiding principle in the long term. The 
discovery of Nor98 and other atypical scrapie strains could also give a possible 
explanantion to the existence of the VRQ haplotype. The existence of this 
haplotype has been perplexing because it is not known to bestow advantages to the 
host, on the contrary, it is frequently fatal for sheep exposed to classical scrapie. A 
haplotype of this sort would be expected to be eliminated from the population by 
natural selection, why is it not so? Perhaps the answer lies in the presence of these 
newly discovered atypical scrapie strains? Could it in fact be that the VRQ 
haplotype conferred resistance to past strains? If that is the case, it is a strong 
reason for maintaining a large diversity of PrP haplotypes in sheep populations. 
More information about this newly discovered type of TSE agent, its occurrence in 
countries free of scrapie or BSE disease, and its capability for intra- and inter-
species transmission is needed, to be able to assess its implications in terms of 
veterinary public health.  
 
CWD – an emerging prion disease 
CWD was first recognized in 1967 as a clinical syndrome of unknown etiology 
among captive mule deer (Odocoileus hemionus) at wildlife research facilities in 
Colorado and Wyoming in the US (Watts, Balachandran & Westaway, 2006; 
Williams, 2003). It was recognized as a spongiform encephalopathy by 
histopathological examination of the CNS from affected animals in 1978  18
(Sigurdson & Miller, 2003; Williams & Young, 1980; Williams & Young, 1982). 
Biochemical and histopathological features have been described comprehensively 
and fall within the mainstream of prion diseases (Williams, 2005). There are only 
three species of Cervidae (the deer family) known to be susceptible to CWD in the 
field: mule deer, white-tailed deer (Odocoileus virginianus), and Rocky Mountain 
Elk (Cervus elaphus nelsoni). 
 
CWD have two remarkable features that call for attention. First, it is the only 
prion disease known to (naturally) affect free-ranging animals. Second, it is a 
disease where horizontal transmission is very common (Mathiason et al., 2006; 
Miller, Wild & Williams, 1998; Miller et al., 2000). Related to the second point, 
CWD can reach impressive attack rates in affected populations, around 30% in 
some local populations of deer and effectively 100% in captive research facilities 
(Williams, 2005), and is spreading across North America in both captive and free-
ranging populations. This spread has made CWD a disease of considerable 
concern for the captive elk and deer industry. Even though only three species of 
the Cervidae are known be naturally infected at present, there are concerns of the 
CWD prion crossing the species barrier into new hosts, including humans 
(Anonymous, 2003; Mathiason, et al., 2006; Raymond, et al., 2000). If also moose 
(Alces sp.) can be naturally infected (Watts, Balachandran & Westaway, 2006; 
Williams, 2005), the scenario for CWD reaching new geographical areas are 
worrying.  
 
The PrP gene  
The PrP gene is highly conserved in mammals, and paralogues are present in 
turtles (Simonic et al., 2000), amphibians (Strumbo et al., 2001) and fish (Premzl 
et al., 2004; Rivera-Milla, Stuermer & Malaga-Trillo, 2003). The complete open 
reading frame (ORF) of all known vertebrate PrP genes is situated within a single 
exon (Basler et al., 1986; Gabriel et al., 1992; Hsiao, et al., 1989; Premzl, et al., 
2004; Prusiner, 1998; Westaway et al., 1987; Windl et al., 1995). The mouse, 
sheep, cattle, and rat PrP genes contain three exons with the ORFs in exon 3 (Saeki 
et al., 1996; Westaway et al., 1994a; Westaway et al., 1991; Westaway et al., 
1994c; Yoshimoto et al., 1992) which is analogous to exon 2 of the human and 
syrian hamster gene which both only contain 2 exons (Basler, et al., 1986; 
Kretzschmar et al., 1986b; Lee et al., 1998; Makrinou, Collinge & Antoniou, 
2002; Puckett et al., 1991). PrP mRNA is expressed at high levels in neurons 
(Kretzschmar et al., 1986a) but is also expressed in a variety of non-neural tissues 
throughout the body (Brown et al., 1990; Han, Liu & Zhao, 2006; Makrinou, 
Collinge & Antoniou, 2002). 
 
Classical genetic analysis identified scrapie incubation (Sinc)/prion incubation 
(Prn-i) as the major gene controlling mouse scrapie incubation time. It is important 
to acknowledge that the Sinc/Prn-i gene and the PrP gene (Prnp) are one and the 
same (Carlson et al., 1986; DeArmond & Prusiner, 2003; Moore et al., 1998; 
Westaway, et al., 1987). 
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The doppelgänger of PrP  
16 kb downstream of the PrP gene, an ORF is present that encodes a protein, 
which shares significant homology with PrP
C (Moore et al., 1999). It is probably 
the result of a gene duplication of a single ancestral gene which gave rise to Prnp 
and Prnd, as it is highly homologous to the C-terminal two-thirds of PrP. The 
protein of 179 residues was named Dpl for “downstream of the Prnp locus” (or 
“doppel”) (Moore, et al., 1999). The Prnd gene coding for Dpl is evolutionarily 
conserved from humans to sheep and cattle, suggesting an important function of 
Dpl (Tranulis et al., 2001). In fact, the absence of Dpl causes male sterility in mice 
(Behrens et al., 2002). Spermatozoa from Dpl-deficient mice seem to be incapable 
of undergoing the normal acrosome reaction that is needed to penetrate the zona 
pellucida of the ovum. Thus, mice lacking Prnd identify Dpl as a crucial regulator 
of male gametogenesis. At present, the experimental data is inconclusive in regard 
to the possible involvement of Dpl in prion disease pathogenesis (Aguzzi & 
Polymenidou, 2004; Rossi et al., 2001). 
 
Cellular biology of PrP
C 
Investigating the biosynthesis, posttranslational processing, cellular localization, 
and trafficking of PrP
C and PrP
Sc allows examination of the properties of PrP in the 
setting of native cellular structures. The function of PrP
C and co-factors that are 
likely to be critical in mediating the efficient conversion of PrP
C into PrP
Sc can 
only be elucidated in detail in a cell culture model system. 
 
Expression and function of PrP
C 
PrP
C is a glycoprotein, normally attached to the surface of neurons, especially 
synaptic membranes, and glia cells of the brain and spinal cord in all mammals via 
a glycophosphatidylinositol (GPI) anchor (Moser et al., 1995; Stahl et al., 1987) 
(see below Figure 3). The expression pattern of PrP
C is diverse and 
developmentally regulated in skeletal muscle, kidney, heart, secondary lymphoid 
organs and the CNS, suggesting a wide-ranging and conserved function of the 
protein (Aguzzi & Polymenidou, 2004; Bendheim et al., 1992; Caughey, Race & 
Chesebro, 1988; Dodelet & Cashman, 1998; Ford et al., 2002; Harris, Lele & 
Snider, 1993; Manson et al., 1992; Miele et al., 2003; Moser, et al., 1995).  
 
Establishing the physiological role of PrP
C may be important for understanding 
of the disease state, since the protein may fail to carry out its normal function 
when it is converted into the PrP
Sc isoform. In the words uttered by the Nobel 
laureate Dr Kurt Wüthrich at the 2003 Prion Conference in Munich: “PrP
C is the 
key” in response to the endless number of experiments done exclusively on the 
disease-associated isoform, PrP
Sc. To add to the conundrum of PrP, mice devoid of 
PrP do not display any defects (Bueler et al., 1992), not even when ablation is 
induced postnatally in neurons (Mallucci et al., 2002). In fact, the only definite 
phenotype of PRNP
0/0 mice is their resistance to prion infection (Bueler, et al., 
1993)! 
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Its expression in most tissues and its amino acid (aa) conservation throughout 
evolution would argue for PrP
C having a fundamental function. However, the 
function of PrP
C is still enigmatic. Its localization on the extracellular face of the 
cell membrane would be consistent with roles in cell adhesion and recognition, 
ligand uptake, or transmembrane signalling. Some of the many functions that have 
been attributed to PrP
C relates to immunoregulation, signal transduction, copper 
binding, synaptic transmission, superoxide dismutase activity, cell adhesion, 
induction of apoptosis or protection against apoptosis to name but a few (Brown et 
al., 1997; Brown et al., 1999; Kurschner & Morgan, 1995; Mouillet-Richard et al., 
2000; Sakudo et al., 2003; Schmitt-Ulms et al., 2001). PrP
C is expressed on long-
term, re-populating hematopoietic stem cells (Zhang et al., 2006) and it positively 
regulates neural precursor proliferation during developmental and adult 
mammalian neurogenesis (Steele et al., 2006). Recently PrP
C has also been 
implicated in cell-cell communication via exosomal release pathways (Fevrier et 
al., 2004) and long-term memory mechanisms (Papassotiropoulos et al., 2005).  
 
  10        20        30        40        50        60        70              
              ....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
Cattle        MVKSHIGSWILVLFVAMWSDVGLCKKRPKPGGGWNTGGSRYPGQGSPGGNRYPPQGGGGWGQPHGGGWGQ  
Sheep         ......................................................................  
European elk  ......................................................................  
Reindeer      ......................................................................  
Human           MANL.C.M......T...L........... .....................................  
Mouse           MANL.Y.L.A...T..T............. ........................ T...........  
Rabbit          MA.L.Y.M.L....T...........................S............. ...........  
 
                       80        90       100        110       120       130                
              ....|....|....|....|....|....|....| ....|....|....|....|....|....|.... 
Cattle        PHGGGWGQPHGGGWGQPHGGGWGQPHGGGGWGQGG THGQWNKPSKPKTNMKHVAGAAAAGAVVGGLGGY  
Sheep         ........        ................... S.S...............................  
European elk  ........        ................... ..S...............................  
Reindeer      ........        ................... ..S...............................  
Human         ........        ............. .....G..S..............M................  
Mouse         ....S...        ....S........ .....G..N...........L...................  
Rabbit        ........        ............. ..... ..N..G.......S....................  
 
             140       150       160       170       180       190       200              
              |....|....|....|....|....|....|....|....|....|....|....|....|....|.... 
Cattle        MLGSAMSRPLIHFGSDYEDRYYRENMHRYPNQVYYRPVDQYSNQNNFVHDCVNITVKEHTVTTTTKGENF  
Sheep         ..............N...........Y..............................Q............  
European elk  ..............N...........Y..............N...T...........Q............  
Reindeer      ..............N...........Y..............N...T...........Q............  
Human         .........I...........................M.E...............I.Q............  
Mouse         .........M....N.W.........Y............................I.Q............  
Rabbit        ..............N...........Y..................S...........Q............  
 
             210       220       230         240       250       260           
              |....|....|....|....|....|...  .|....|....|....|....|.... 
Cattle        TETDIKMMERVVEQMCITQYQRESQAYYQ  RGASVILFSSPPVILLISFLIFLIVG  
Sheep         ......I......................  ..........................  
European elk  .............................  ..........................  
Reindeer      .............................  ..........................  
Human         ....V...............E........  ..S.MV....................  
Mouse         ....V...........V....K......DGR.SS.TV....................  
Rabbit        ......I..............Q....A..  .A.G.L....................  
 
Figure 1. Amino acid alignment of PrP from seven species. Protein accession nos. in the 
NCBI database (http://www.ncbi.nlm.nih.gov/) are P10279 (Cattle), NP_001009481 
(Sheep), AAT77255 (European elk), AAT77253 (Reindeer), P04156 (Human), NP_035300 
(Mouse), AAC48697 (Rabbit). Amino acid numbering is according to boPrP (6OR). The aa 
residues have been coloured according to their polarity characteristics as acidic (red), basic 
(blue), hydrophobic (light orange), and uncharged polar (black), respectively. The 
alignment was done using ClustalW and the figure was generated in BioEdit (v. 7.0.5). 
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Biosynthesis of PrP
C 
The PrP encoded by the mammalian PrP gene comprise approximately 250 aa 
(Fig. 1) and contains a number of discrete domains. It contains an N-terminal 
signal peptide, a series of five proline- and glycine-rich octapeptide repeats, a 
central hydrophobic region that is highly conserved, and a C-terminal hydrophobic 
portion that functions as a signal for GPI anchor addition (Figure 2). The human 
PrP gene encodes 253 aa and the sheep 256 aa. Interestingly, in cattle 
approximately 90% is homozygous for a PrP with 6 octapeptide repeats (6OR) and 
the remaining 10% heterozygous for PrP with 5 and 6 repeats (Heaton et al., 2003; 
Jeong et al., 2005; Nakamitsu et al., 2006; Sander et al., 2004). Cattle 
homozygous for 5 octapeptide repeats have been found, but are very rare 
(Nakamitsu, et al., 2006). Strictly speaking, in cattle the octapeptide repeat region 
consists of 1 nonapeptide followed by 4(3) octapeptides followed by 1 
nonapeptide: 
 
nonarepeat 1: aa 54 - 62    (PQGGGGWGQ) 
octarepeat 1: aa 63 - 70    (PHGGGWGQ) 
octarepeat 2: aa 71 - 78    (PHGGGWGQ) 
octarepeat 3: aa 79 - 86    (PHGGGWGQ) 
octarepeat 4: aa 87 - 94    (PHGGGWGQ) 
nonarepeat 2: aa 95 - 103   (PHGGGGWGQ) 
 
Amino acid numbering is according to the 6OR bovine PrP (P10279 in the NCBI 
database) sequence which consists of 264 aa. The four octarepeats are identical 
while the two nonarepeats differ at one position. 
 
 
 
Figure 2. Schematic representation of the boPrP primary translational product. Numbering 
in the figure is according to the 6OR boPrP. N-terminal signal sequence (1–24, green box), 
six octarepeats (54–103, red boxes), hydrophobic region (123–150, gold box), C-terminal 
signal sequence for GPI attachment (242–264, green box), N-linked glycosylation at N192 
and N208 (CHO), disulphide bond between C190 and C225 (S-S), and GPI-anchor is attached 
at aa 241. The cleavage site between K121 and H122 generating the N1 and C1 fragments is 
indicated by a grey arrowhead and the putative cleavage site for shedding of PrP in the 
region 238-QRGA-241 is indicated by a black arrowhead. 
 
 
PrP
C is synthesized in the rough endoplasmic reticulum (ER) and transits the 
Golgi on its way to the surface, similar to other membrane proteins. Throughout 
the biosynthesis of PrP
C, it undergoes a number of different posttranslational 
modifications. These modifications include cleavage of the N-terminal signal 
peptide, addition of N-linked oligosaccharide chains at two sites (N192 and N208), 
formation of a single disulfide bond (C190 and C225), and addition of a GPI anchor  22
(Haraguchi et al., 1989; Harris, 1999; Stahl, et al., 1987; Turk et al., 1988; Zhao et 
al., 2006). In the ER N-linked oligosaccharides of high-mannose type are added 
that are sensitive to endoglycosidase H treatment and the GPI-anchor is added 
after cleavage of the C-terminal hydrophobic portion. Next, these oligosaccharides 
are modified in the Golgi to complex-type sugar chains that contain sialic acid and 
gain resistance to endoglycosidase H (Caughey et al., 1989; Zhao, et al., 2006).  
 
 
 
Figure 3. Model of glycosylated huPrP indicating positions of N-linked glycans (in blue 
spacefill), the single disulphide bond joining helices 2 and 3 (yellow bond), and the GPI-
anchor that inserts into the outer leaflet of the plasma membrane. From (Collinge, 2001). 
 
When both asparagine-linked consensus sites are glycosylated, the diversity of 
oligosaccharide structures yields over 400 different forms of PrP (Endo et al., 
1989). In combination with the six most commonly occurring forms of the GPI 
anchor found on PrP (Stahl et al., 1992) the diversity of distinctly modified PrP 
molecules is vast. The size of the complex oligosaccharides and the GPI anchor 
moiety in relation to the polypetide is considerable as can be seen in Figure 3. 
 
Molecules with either one or both N-glycosylation attachment sites mutated 
display a number of biochemical characteristics of PrP
Sc (Rogers et al., 1990). A 
conclusion of these experiments could be that wild-type PrP
C has an inherent 
propensity to take on some properties of PrP
Sc in the course of its normal   23
conformational maturation but that N-linked oligosaccharides safeguard against 
this transformation. The observation that different prion strains exhibit 
characteristic patterns of glycosylation could be related to this inherent propensity 
of PrP (Collinge et al., 1996; DeArmond et al., 1997; Kascsak et al., 1986; Monari 
et al., 1994; Parchi et al., 1996). 
 
Posttranslational cleavage of PrP
C 
Work with transfected cell lines, brain tissue, cerebrospinal fluid, blood, and tissue 
from a number of organs, have shown that PrP
C is subjected to two 
posttranslational cleavages during the course of its normal metabolism (Borchelt et 
al., 1993; Caughey, et al., 1989; Caughey et al., 1988; Chen et al., 1995; Harris et 
al., 1993; Jimenez-Huete et al., 1998; Klingeborn et al., 2006a; Perini, Frangione 
& Prelli, 1996; Tagliavini et al., 1992; Taraboulos et al., 1995; Tveit et al., 2005; 
Vincent et al., 2000; Vincent et al., 2001; Volkel et al., 2001; Yadavalli et al., 
2004; Zhao, et al., 2006). The first cleavage occurs within a segment of 
hydrophobic aa (huPrP 112-139; boPrP 123-150) that is almost completely 
conserved in all vertebrate PrPs (see Figure 1 and (Schatzl et al., 1995)). The 
resulting N-terminal fragment, N1, is recovered in the extracellular space and the 
C-terminal fragment (C1) with alternative N-termini at H111 or M/V112 (huPrP 
numbering; K121/H122 in boPrP) remains attached to the cell surface via its GPI 
anchor (Chen, et al., 1995; Harris, et al., 1993; Vincent, et al., 2000; Vincent, et 
al., 2001; Zhao, et al., 2006). Our data indicate that this cleavage, denoted C1 
cleavage, occurs beyond the trans-golgi network (TGN) but prior to or very soon 
after arrival at the cell surface (Zhao, et al., 2006). Similar observations have been 
made by other groups (Taraboulos, et al., 1995; Tveit, et al., 2005), while some 
groups suggest that it occurs in an endocytic compartment following endocytosis 
(Harris, et al., 1993; Shyng, Huber & Harris, 1993). Differences in the protease 
activity in subcellular compartments could be the reason for the diverging 
observations of proteolytic processing between cell lines.  
 
The second cleavage occurs at the extreme C-terminal end, probably only 3 aa 
from the GPI anchor by a zinc metalloprotease(s) and results in the shedding of C1 
into the extracellular medium (Borchelt, et al., 1993; Parkin et al., 2004; Stahl et 
al., 1990; Zhao, et al., 2006). The time course of this second cleavage suggests 
that it possibly takes place during cycling between the cell surface and an 
endocytic compartment with a transit time of approximately 60 min (Klingeborn, 
et al., 2006a; Shyng, Huber & Harris, 1993; Zhao, et al., 2006). Interestingly, in 
some cell lines where this specific protease activity is low in these compartments, 
a minor release by a cleavage within the GPI anchor have been reported (Harris, et 
al., 1993; Shyng, Huber & Harris, 1993). This cleavage is affected in a dose-
dependent manner by the amount of fetal calf serum (FCS) included in the cell 
culture medium, implicating an exogenous phospholipase (Harris, et al., 1993; 
Klingeborn, et al., 2006a; Parizek et al., 2001; Shyng, Huber & Harris, 1993). 
Supporting this notion, phospholipase-mediated cleavage cannot be detected in the 
absence of FCS in our hands (Klingeborn, et al., 2006a) and was recently reported 
to only be detected after induction by lipid raft-disrupting agents (Parkin, et al.,  24
2004) suggesting that this type of cleavage is non-constitutive and possibly not 
present under physiological conditions. 
 
The C1 cleavage is very fast, so at steady-state a major fraction of PrP
C will be 
in the form of C1, and this is also supported by observations both in vitro and in 
vivo in many species (Chen, et al., 1995; Jimenez-Huete, et al., 1998; Klingeborn, 
et al., 2006a; Klingeborn, et al., 2006b; Liu et al., 2001; Takekida et al., 2002; 
Tveit, et al., 2005; Zhao, et al., 2006), see also Figure 4. Both of these proteolytic 
processing events occur relatively quickly in relation to the half-life of the protein. 
C1 is detected as soon as 5-20 min after translation and the soluble form, C1-S, is 
recovered in the extracellular medium 60-75 min after translation. The halflife of 
C1 is long, probably in excess of 24 hours (Klingeborn, et al., 2006a). 
Interestingly, in some cell lines a more complete degradation of PrP, almost 
completely without C1 cleavage and shedding, have been described (Caughey, et 
al., 1989; Zhao, et al., 2006). The underlying cause for this divergence in PrP 
metabolism is not known at this stage.  
 
 
 
Figure 4. Western immunoblotting of PrP
C (mAb 6H4) in brain homogenates from a 
number of  species demonstrating the C1 fragment. Cattle (lanes 1 and 9), sheep (lanes 2 
and 10), European elk (lanes 3 and 11), roe deer (lanes 4 and 12), reindeer (lanes 5 and 13), 
fallow deer (lanes 6 and 14), red deer (lanes 7 and 15), and molecular mass markers (lanes 8 
and 16; 20, 30 and 40 kDa bands are visible). Removal of oligosaccharides by treatment 
with PNGase F and positions of full length (F) and the C1 fragment (C1) of PrP
C are 
indicated. (Simonsson, M., Klingeborn, M., and Linné, T., unpublished) 
 
The physiological importance of these cleavages is unknown. Similar to 
polypeptide growth factors that are released by cleavage of membrane-bound 
precursors, the N1 could serve as a biologically active ligand (Nakada-Tsukui, 
Watanabe & Kobayashi, 1999; Parkin et al., 2002; Zheng et al., 2004). In fact, 
some of the proteases implicated in the C1 cleavage releases a number of 
biologically active ligands (Parkin, et al., 2004; Vincent, et al., 2000; Vincent, et 
al., 2001; Zhao, et al., 2006). PrP
C could possibly function as a cell surface 
receptor and the cleavages would in that case correspond to mechanisms of 
receptor down-regulation.  
 
Exosome-mediated release of PrP 
In addition to protease-mediated shedding of PrP, another constitutive pathway of 
release of PrP have recently been discovered. This type of release is exosome-  25
mediated and is responsible for <1% of the PrP recovered from the extracellular 
medium (Fevrier, et al., 2004; Klingeborn, et al., 2006a; Leblanc et al., 2006; 
Rajendran et al., 2006). Exosomes are 50- to 90-nm vesicles of endosomal origin 
that are released by many cell types into the extracellular environment upon fusion 
of endosomes known as multivesicular bodies (MVBs), with the cell surface 
(Stoorvogel et al., 2002; Thery, Zitvogel & Amigorena, 2002). They are thought to 
be play an important role in intercellular communication (Stoorvogel, et al., 2002; 
van Niel et al., 2006) and further studies of this pathway of PrP
C release could 
reveal interesting details about functional aspects of PrP
C. It has been reported 
recently that purified exosomes from scrapie-infected cells could infect both cell 
cultures and bioassay mice very efficiently (Fevrier, et al., 2004). Since only very 
few molecules of PrP
Sc are needed to transmit prion infection (Silveira et al., 2005) 
even a minute pathway of release such as the exosome-mediated could still be 
important for cell-to-cell spreading of prion infection. The importance of the 
exosomal release of PrP
Sc for the spread of prion infection remains to be 
investigated. 
   
Cellular biology and propagation of PrP
Sc 
In the case of conventional virus diseases, experimental analysis depends largely 
on the ability to grow the infectious agent in cultured cells, and the same has been 
true for prion diseases. PrP
Sc is produced by several cell types following prion 
infection in vivo, including neurons, astrocytes, and lymphoreticular cells (Blattler 
et al., 1997; DeArmond et al., 1987; Diedrich et al., 1991; Raymond, et al., 1997). 
It has however been quite difficult to achieve cell lines stably infected with prions. 
Most of the cell lines that are stably infected are neuronally derived but some of 
non-neuronal origin have also been established (Archer et al., 2004; Butler et al., 
1988; Clarke & Haig, 1970; Race, Fadness & Chesebro, 1987; Raymond et al., 
2006; Sabuncu et al., 2003; Schatzl et al., 1997; Vorberg et al., 2004). These 
stably infected cells continuously produce low levels of PrP
Sc, which can be 
recognized by its proteinase resistance and detergent insolubility and by its 
infectivity in animal bioassays.  
 
Properties of stably prion infected cell lines  
A crucial property of a cell line which enable it to propagate prions is similarity 
between the sequence of the endogenous PrP
C and that of the donor PrP
Sc 
(Weissmann, 2004). Even small differences not only prevent conversion of the 
mismatched PrP
C (Priola & Chesebro, 1995) but also have a dominant-negative 
effect on the conversion of matching PrP
C in the same cell (Kaneko et al., 1997). 
Stably infected cells do not display any obvious cytopathology, which might seem 
surprising. However, this finding is probably connected with the properties that 
enable stable prion infection and is explained by the “dynamic susceptibility 
model” proposed by Weissmann (Weissmann, 2004). This model suggests that the 
ability of a cell to propagate prions, all genetic characteristics being alike, rely on 
the ratio of prion synthesis to degradation. The rate of prion formation must equal 
or surpass twice that of its degradation, or the infected condition will be eliminated 
at some time after exposure to exogenous prions. This is a consequence of  26
infectivity per cell being halved after each cell division. However, a rate of 
formation that is more than twice that of degradation will result in a steady 
accumulation of PrP
Sc that might eventually lead to cell death. Therefore, 
maintenance of a precise equilibrium of synthesis versus degradation is crucial to 
attain persistent infection. Interestingly, cell lines that are susceptible to certain 
prion strains might not be susceptible to other strains and this strain susceptibility 
differs between cell lines. The underlying mechanisms for these observations are 
not known at present. 
 
Formation of PrP
Sc in cultured cells 
It has been established that PrP traverses the mid-Golgi stack before acquiring 
protease resistance. About 1 h after the formation of PrP
Sc, its N-terminus is 
removed by a proteolytic process, resulting in a fragment denoted C2, that is 
inhibited by ammonium chloride, chloroquine, leupeptin, calpain inhibitors and 
monensin, arguing that it is an event occurring in the late endocytic pathway or 
lysosome (Caughey et al., 1991; Taraboulos et al., 1992; Yadavalli, et al., 2004). 
These results also suggest that the ER is unfit for the synthesis of PrP
Sc. The C2 
fragment is identical with the fragment produced by PK-treatment of PrP
Sc, PrP 
27-30 (Chen, et al., 1995; Yadavalli, et al., 2004). Furthermore, surface iodination 
of infected cells results in incorporation of radiolabel into PrP
Sc after a chase 
period, arguing that PrP molecules transit the plasma membrane prior to 
conversion into PrP
Sc (Caughey, et al., 1991). Treatment of cells with 
phosphatidylinositol-specific phospholipase C (PIPLC) or proteases inhibits the 
production of PrP
Sc, probably by removal of the PrP
C substrate from the cell 
surface (Borchelt, Taraboulos & Prusiner, 1992; Caughey & Raymond, 1991). The 
formation of PrP
Sc is also diminished by lovastatin-mediated depletion of cellular 
cholesterol but insensitive to ammonium chloride. Thus, it seems likely that the 
formation of PrP
Sc occur within a non-acidic compartment bound by cholesterol-
rich membranes, possibly glycolipid-rich microdomains, where the metabolic fate 
of PrP
C is determined (Taraboulos, et al., 1995). Presumably, the conversion of 
PrP to the protease-resistant state occurs in the plasma membrane or along the 
endocytic pathway before PrP
Sc is exposed to endosomal and lysosomal proteases 
(Caughey, et al., 1991; Chen, et al., 1995; Taraboulos, et al., 1992; Yadavalli, et 
al., 2004).  
 
In scrapie-infected Syrian hamster (SHa) brain full-length PrP
Sc is also detected, 
indicating that some but not all PrP
Sc molecules accumulating in the brain during 
scrapie lose their N-terminus. Thus, lysosomal trimming is not an obligatory step 
in PrP
Sc synthesis; instead, the lysosomal accumulation of PrP
Sc may reflect 
ineffective attempts of cells to degrade unwanted proteins (Taraboulos, et al., 
1992). Because the processing of PrP
C appears to be mainly nonlysosomal 
(Klingeborn, et al., 2006a; Taraboulos, et al., 1995; Yadavalli, et al., 2004; Zhao, 
et al., 2006), PrP
Sc must get some sorting signal that targets it to secondary 
lysosomes. Investigating the nature of such a signal may give important 
information regarding the structural difference between the PrP isoforms. One 
possibility is that aggregation of PrP
Sc causes its endocytosis. 
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Once formed, PrP
Sc appears to be metabolically stable for 24 to 48 h, in contrast 
to PrP
C, which turns over with a half-life of 4 to 6 h (Borchelt et al., 1990; 
Borchelt, Taraboulos & Prusiner, 1992; Caughey & Raymond, 1991). Only a 
minority of PrP
C molecules, around 5%, are converted to PrP
Sc in infected cells, 
with the remainder being processed and degraded by pathways similar to those 
found in uninfected cells (Borchelt, et al., 1990; Taraboulos et al., 1990; 
Taraboulos, et al., 1995). 
 
Propagation of PrP
Sc 
There are currently two models favoured to explain the mechanistic aspects of the 
conversion of PrP
C to PrP
Sc (Figure 5). The “template-directed refolding model” 
(also known as the “monomer-directed heterodimer model”) predicates that PrP
C 
unfolds to some extent and refolds under the influence of a PrP
Sc molecule that 
acts as a template and possibly along with a hypothetical molecular chaperone 
(Kaneko, et al., 1997; Prusiner, Torchia & Westaway, 1991; Telling et al., 1995). 
In this case, the kinetic barrier between PrP
C and PrP
Sc is overcome by the 
catalytic action of PrP
Sc, possibly in conjunction with the chaperone. Experimental 
evidence is compatible with this theory, however no positive proof in its favour 
has come forward to date.  
 
Figure 5. Models for the conformational conversion of PrP
C into PrP
Sc. (A) A schematic 
representation of the “template-directed refolding model”. (B) Representation of the 
“seeded nucleation model”. Details are described in the text. Figure from Aguzzi & 
Polymenidou (2004). 
 
The “seeded nucleation model” (also known as the “nucleation-dependent 
polymerization model”) on the other hand, postulates that PrP
C is in equilibrium 
with PrP
Sc (or a precursor thereof), with the equilibrium heavily in favour of PrP
C, 
and that PrP
Sc is only stabilized when it adds to a crystal-like seed of PrP
Sc (Come, 
Fraser & Lansbury, 1993; Jarrett & Lansbury, 1993). From this model follows that 
monomer addition will proceed rapidly as soon as a seed is present. To explain the 
exponential increase of PrP
Sc during infection, fragmentation of aggregates must  28
occur occasionally. Fascinatingly, it also follows that minute amounts of PrP
Sc is 
present at any time in a normal organism. If this was the case, it would be 
impossible for PrP
Sc to represent the infectious agent since it would be ubiquitous. 
The seeded nucleation model suggest that the infectious agent would consist of a 
highly ordered aggregate of PrP
Sc molecules. The aggregated condition would be 
an inherent feature of infectivity, i.e. monomeric PrP
Sc would be harmless but 
might be inclined to incorporate into PrP
Sc aggregates. These predictions have in 
fact been confirmed by the recent findings by Silveira and colleagues, who found 
that the most infectious prion protein particles were non-fibrillar particles of 14-28 
PrP molecules (Silveira, et al., 2005). Furthermore they found that the infectivity 
was substantially lower in large fibrils and virtually absent in oligomers of five or 
less PrP molecules. 
 
In the case of yeast prions, as discussed below (Prion strains), experimental data 
strongly support the “seeded-nucleation model”, and this also applies to 
mammalian prions as recently reported (Caughey et al., 1997; Harper & Lansbury, 
1997; Jones & Surewicz, 2005; Silveira, et al., 2005; Surewicz, Jones & Apetri, 
2006; Vanik, Surewicz & Surewicz, 2004). As discussed below regarding the 
“protein misfolding cyclic amplification” (PMCA) technique, the data available 
with the use of this method also strongly support the “seeded-nucleation model” of 
prion replication (Soto, Estrada & Castilla, 2006). 
 
Prion strains 
An extraordinary phenomenon is the existence of discrete prion strains, originally 
typified by the incubation time and neuropathology they elicit in a certain host 
(Bruce, 2003). As distinct mammalian prion strains can be propagated indefinitely 
in hosts homozygous for the PrP gene, the protein-only hypothesis stipulates that 
the strain-specific features must be enciphered in some property of the pathogenic 
PrP other than its amino acid sequence, such as posttranslational modification or 
conformation. Different strains are frequently associated with PrP
Sc species 
differing in physical features such as susceptibility to PK digestion, electrophoretic 
mobility following PK treatment reflecting a diversity of amino-termini as a result 
of different cleavage sites, stability toward denaturing agents, or the proportions of 
di-, mono-, and unglycosylated forms. 
 
“Conformational templating” at the protein level was first demonstrated by 
showing that when radioactively labelled PrP
C was incubated with PrP
Sc derived 
from strains with different electrophoretic mobilities of their PK-resistant core 
fragment, the radioactive conversion product manifested the strain-specific 
attributes of the PrP
Sc template (Caughey, et al., 1999). Experimental approaches 
with yeast [PSI
+] prions irrefutably established that different strain characteristics 
are associated with distinct fibrillar conformations of the Sup35 protein (King & 
Diaz-Avalos, 2004; Sparrer, et al., 2000; Tanaka, et al., 2004). In one approach, 
fibrous aggregates of Sup35 prion domains from three distinct [PSI
+] yeast strains 
were isolated, respectively. Preparations of bacterially expressed, tagged sup35 
prion domains were seeded with these aggregates and the resulting fibers were 
introduced into yeast, where they evoke the [PSI
+] state characteristic for the   29
donor lines (King & Diaz-Avalos, 2004). The same conclusion was drawn from 
the results of another experimental approach: at different temperatures, amyloids 
formed de novo from the Sup35 prion domain adopted discrete, stably propagating 
conformations, as characterized by thermal stability and electron paramagnetic 
resonance spectroscopy, and infection of yeast with these amyloids led to distinct 
[PSI
+] strains (Tanaka, et al., 2004). 
 
With regard to mammalian prion strains, even though recombinantly expressed 
PrP (rPrP), both truncated and full-length, can be converted into fibrillar amyloid 
forms that can be propagated by seeding (Bocharova et al., 2005; Jones & 
Surewicz, 2005), the infectivity, if any, of such preparations is low (Legname, et 
al., 2004). Correlation of structurally diverse fibrils with distinct prion strains has 
not been achieved to date, but interesting insights concerning their seeding 
properties have been acquired (Jones & Surewicz, 2005; Legname, et al., 2005; 
Surewicz, Jones & Apetri, 2006). 
 
Species and strain barriers 
Inter-species prion transmission is often restricted by a “transmission barrier” that 
is typified by prolonged incubation time, that the attack rate is incomplete, or that 
clinical disease is lacking. In spite of absence of clinical signs, prion replication, 
PrP
Sc accumulation, and histopathological changes may occur late after infection 
(Hill & Collinge, 2003). Incubation time, is not a straightforward function of prion 
or PrP
Sc accumulation but is influenced by the prion strain, the site of inoculation 
within the brain, and genetic determinants of the host other than the PrP gene. As 
judged by incubation time, transmission of prions from one species to another is 
typically less efficient than intra-species transmission, a phenomenon accredited to 
a “species barrier”. Subsequent transmissions into individuals of the recipient 
species usually lead to a shorter incubation time than on primary passage. Prions 
therefore seem to “adapt” to the new host. The transmission barrier between 
species is ascribed to a mismatch between the amino acid sequence of the donor 
PrP
Sc and the recipient PrP
C, and in many cases substitution of the PrP gene of the 
mouse by that of the prion donor eliminates the barrier. “Adaptation” is due to the 
formation of PrP
Sc consisting of the host PrP (Prusiner, et al., 1998). Even a single 
aa change in the PrP of the recipient can bring about a radical change in incubation 
time (Manson et al., 1999) or even practically result in resistance to disease 
(dominant-negative mutations; (Perrier et al., 2002)). Correspondingly, naturally 
occurring polymorphisms of the PrP gene, especially position 129 of the human 
PrP, have a major effect on susceptibility to sporadic and variant CJD (Ward et al., 
2003). 
 
Different mouse prion strains, generated in mice with the same PrP gene, display 
different incubation times in a specific mouse line and this is also the case with 
human-derived vCJD and sCJD prions transmitted to mice (Korth et al., 2003). 
This establishes that properties other than the PrP sequence or the host genotype, 
most likely the conformation of the PrP*, also are involved in dictating incubation 
times. Longer incubation times and low attack rates are credited to a ”strain 
barrier”. The strain and the species barrier most probably have a similar origin,  30
that is the inability of PrP
C to take on a conformation appropriate for efficient seed 
propagation. The difference between the two concepts is that for the “strain 
barrier” conformational space is intrinsic to one particular PrP sequence while for 
the “species barrier” conformational space is co-determined by variation in aa 
sequence. 
 
The pathogenic mechanism 
Prions multiply to high titers in the brain and in some hosts in spleen, albeit to a 
lower level. Spongiform degeneration, astrocytosis, and neuronal cell death 
accompany prion multiplication in the CNS. The pathogenic mechanism is still 
unclear, but is not due to the depletion of PrP
C since PrP gene knock out mice, 
whether inborn or induced post-natally, remain healthy (Bueler, et al., 1992; 
Mallucci, et al., 2002). PrP
Sc accumulates in the CNS and is in some instances 
deposited as an amyloid and has therefore been indicted as the toxic entity causing 
neuronal apoptosis and giving rise to disease (DeArmond & Prusiner, 2003). A 
number of experiments have shown that neurons devoid of PrP
C are not damaged 
by PrP
Sc (Brandner et al., 1996; Bueler et al., 1994). An interesting finding in this 
aspect is that when the neuronal expression of PrP in mice was prevented by 
conditional knock out 7-8 weeks after intracerebral inoculation, vast amounts of 
infectivity and PrP
Sc accumulated in astrocytes without exhibiting clinical 
symptoms or evidence of neuronal damage (Mallucci et al., 2003). A toxic 
function gain by a PrP isoform that is different from PrP
Sc is therefore a definite 
possibility. This PrP isoform could be congruent with PrP* or yet another isoform 
distinct from PrP
C and PrP
Sc. Further work is needed to understand the 
biochemical pathways leading to pathogenicity, whether triggered by PrP
Sc, PrP* 
or some other isoform of PrP.  
 
Figure 6. Structure of boPrP
C determined by NMR. Helices are green, -strands are cyan, 
segments with nonregular secondary structure within the C-terminal domain are yellow, and 
the flexibly disordered ‘‘tail’’ of residues 23–121 is represented by 108 yellow dots, each of 
which represents a residue of the tail (the numeration for huPrP is used). Adapted from 
Lopez Garcia et al. (2000). 
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Conformations of PrP 
The three-dimensional structure of PrP is highly conserved between species 
(Wuthrich & Riek, 2001). The mature boPrP
C (boPrP aa 25-241) include an N-
terminally flexible disordered “tail” comprising aa 25-135, a globular domain 
extending from residue 136-238, and a short flexible chain end of aa 239-241, 
respectively (Figure 6). The globular domain contains three alpha-helices 
comprising the residues 155-165, 184-205, and 211-237, and a short anti-parallell 
beta-sheet comprising the residues 139-142 and 172-175 (Lopez Garcia et al., 
2000; Zahn et al., 2000). Helices 2 and 3 are linked by the only disulfide bond in 
boPrP (C190 and C225).  
 
The hydrophobicity of PrP
Sc, which is reflected partly by its detergent-
insolubility, have hampered attempts to determine the tertiary structure of PrP
Sc by 
nucleomagnetic resonance (NMR) imaging. Because of the tendency of PrP
Sc to 
form large, heterogenous aggregates, also analysis by high-resolution X-ray 
crystallographic techniques have been difficult (Harris & True, 2006). It would 
thus seem unlikely that monomeric forms of PrP
Sc exist. However, it is clear that 
PrP
Sc have a much higher proportion of beta sheets than PrP
C (45% compared to 
3%), as analysed by Fourier transform infrared spectroscopic methods (Pan et al., 
1993; Prusiner, 1998) . A model of PrP
Sc based on electron microscopic analysis of 
two-dimensional crystals of PrP 27-30 in combination with theoretical 
considerations revealed a stacked, left-handed -helical structure (Govaerts et al., 
2004; Wille et al., 2002) (Figure 7). Based on computer modelling or on structural 
analysis of recombinant PrP or on synthetic PrP peptides that have been induced to 
take on -rich conformations, other models have also been suggested (Lee & 
Eisenberg, 2003). 
 
 
Figure 7. -helical model of PrP 27-30. (Left and right) Top and side views, respectively, of 
PrP 27-30 modelled with a left-handed -helix. Modified from Wille et al. (2002). 
 
Proof of principle – the protein-only hypothesis revisited 
Final proof that the prion comprise only protein would be achieved if pure PrP
C or, 
even better, recombinant PrP (rPrP) produced in E. coli or mammalian cell  32
cultures, could be converted into a form that evokes prion disease. An important 
experiment in this regard was the demonstration that incubation of radioactively 
labelled PrP
C with unlabelled PrP
Sc in a cell-free system gave rise to radioactive 
PrP
Sc, as characterized by its physical features (Caughey, et al., 1999; Kocisko, et 
al., 1994). The in vitro reaction also displayed the species- and strain-specific 
barriers observed in vivo, however, no increase in infectivity could be shown. 
 
The invention of the protein misfolding cyclic amplification (PMCA) technique 
is a significant move ahead in the field of prion research (Saborio, Permanne & 
Soto, 2001). The PMCA mimics in an accelerated manner, the process of prion 
propagation. In PMCA, large amounts of PrP
C are converted using minute 
quantities of a brain-derived PrP
Sc template. Prion-infected brain homogenate is 
diluted approximately 1:10,000 with uninfected brain homogenate, incubated and 
sonicated to fragment aggregates and thereby enhance seeding. Incubation and 
sonication steps are repeated 20 times in a cyclic manner, hence the name of the 
technique. The reaction mixture is then diluted 1:10 into uninfected brain 
homogenate and again subjected to incubation and sonication cycles. After 
repeated rounds of dilution and amplification, the original infected brain 
homogenate have been diluted to a point were the original PrP
Sc is calculated to 
have been completely eliminated. Nevertheless, the level of PrP-res remain 
basically as in the initial 1:10,000 diluted brain homogenate (Castilla et al., 2005). 
Even more important, infectivity is associated with this in vitro amplified PrP-res, 
as shown by animal bioassays. It is worth noting, however, that incubation time in 
the animal bioassay is significantly longer than that elicited by the original brain 
homogenate. This could be due to that the specific infectivity of the newly 
generated PrP
Sc is lower than its “natural” counterpart or because a “strain shift” of 
the prion occurred. This technique convincingly demonstrate that PrP
Sc and 
infectious agent can be generated in vitro; however it does not rule out 
amplification of other molecules, for example nucleic acids, because it is carried 
out with brain homogenate and not with purified components. Furthermore, in a 
recent report Saá and co-workers showed that an optimised version of the PMCA 
technique is more than 4000-times more sensitive than the animal bioassay (Saa, 
Castilla & Soto, 2006). The quantity of PrP
Sc that this modified PMCA is capable 
of detecting is approximately equivalent to 26 molecules of PrP, which is similar 
to recent data on the minimum number of PrP molecules present in a single 
infectious prion particle (Silveira, et al., 2005). Remarkably, this would indicate 
that PMCA may be able to detect as little as a single prion. 
 
Another significant step towards final proof of the protein-only hypothesis is the 
recent reports by Legname and co-workers (Legname, et al., 2004; Legname, et 
al., 2005). In these experiments a  sheet-rich fibrillar preparation made up by 
amino-terminally truncated rPrP (comprising residues 89 to 230) was injected 
intracerebrally into mice overexpressing the same PrP sequence (tg9949 mice). All 
mice developed neurological disease after about 520 days, as compared with an 
incubation time of roughly 160 days caused by the “natural” Rocky Mountain 
Laboratory (RML; also known as Chandler strain (Chandler, 1961)) prion strain. 
Tg9949 mice injected with only PBS were healthy at 620 days; however, their 
later fate was not reported. Brain homogenate from the sick tg9949 mice caused   33
disease after around 260 days when infused into tg9949 mice. Prions in the brains 
of tg9949 mice inoculated with this recombinant amyloid were designated MoSP1 
(mouse synthetic prion strain 1). Significantly, disease could also be transmitted to 
wild-type mice. MoSP1 in tg9949 were characterised in further detail and were 
found to differ in several characteristics from mouse-adapted and other prion 
strains investigated to date (Legname, et al., 2005). Interestingly, passage of 
MoSP1 through wild-type mice changed the properties of this strain to resemble 
those of RML prions. 
            
The authors’ conclusions of these experiments were that the fibrillar preparation 
of rPrP contained “synthetic prions,” perhaps at low levels, and that these were 
amplified or underwent a strain shift (or both) in the tg9949-inoculated mice, 
accounting for the shortened incubation period on further propagation. When 
MoSP1 was passaged into wild-type mice, the incubation period was decreased 
from first to second passage. It was suggested that this difference reflects a 
transmission barrier caused by the difference in PrP sequences between wild-type 
and Tg9949 mice: wild-type mice express full-length MoPrP, and Tg9949 mice 
express only the C-terminal 65% of the protein. The change in characteristics of 
MoSP1 on passage in wild-type mice are reminiscent of the alterations seen when 
Sc237 prions from Syrian hamsters were passaged in Tg mice expressing chimeric 
mouse-hamster (MH2M) PrP (Peretz et al., 2002). Furthermore, the incubation 
times, neuropathologic lesion profiles, and resistance to GdnHCl denaturation 
indicate that MoSP1 is unlike any prion strain previously described and thus 
possibly constitute a new strain (Legname, et al., 2005).  
 
It is, however, worth noting that mice which highly overexpress PrP have been 
shown to spontaneously develop prion-like disease (Chiesa et al., 1998; Westaway 
et al., 1994b), raising concerns over this mouse model (tg9949). It is thus feasible 
that tg9949-transgenic mice, which considerably overproduce PrP, would have 
spontaneously developed prion disease at higher age and that the injection simply 
accelerated this endogenous process. In fact, a crucial control experiment of 
injecting brain homogenate from old, noninoculated tg9949 into young tg9949 
mice and keep them under observation for the appearance of prion disease have 
not been reported.  
 
Notwithstanding, the significance of this experiment should not be ignored, to be 
exact that if prions had not been created in the cell-free system, they must have 
arisen spontaneously in an uninfected mouse, mimicking the sporadic occurrence 
of CJD in humans. The interpretation of the Legname experiments are, 
nevertheless, vital in one respect. If the prions in the tg9949 mice are of 
endogenous origin then the experiments would not be proof of the protein-only 
hypothesis. If prions had been generated in vitro from recombinant PrP, then the 
proof would be indisputable, even if amplification required additional components 
provided by the host, such as RNA (Deleault, Lucassen & Supattapone, 2003). 
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Present investigations 
Aim 
The general aims of this study are to investigate the cellular processing of the 
bovine cellular prion protein and to characterize the molecular features of the 
Nor98 prion.  
 
Results and discussion 
In papers I-III in the appendix, methods used in the present investigations are 
described in detail and will therefore not be recounted in this section. 
 
Paper I: Proteolytic Cleavage and Shedding of the Bovine Prion Protein in 
Two Cell Culture Systems  
BSE is known to give rise to a zoonotic disease (vCJD) (Collinge, 1999) as a result 
of bovine PrP
Sc crossing the species barrier into humans, which motivated us to 
perform a detailed study of the cellular processing, turnover and release of bovine 
PrP
C. 
 
Since PrP contains several posttranslational modifications, an eukaryotic 
expression system is essential for relevant studies of its cellular processing. 
Furthermore, to be able to study all aspects of the processing in detail, high 
expression is needed for short pulse-chase radio-labelling analyses. Semliki forest 
virus (SFV)-vector driven expression of proteins has proven to be an efficient and 
high-level eukaryotic protein expression system (Liljestrom & Garoff, 1991). The 
bovine PrP was cloned into the expression vector pSFV1 and used for expression 
in BHK and N2a cells. The comparison done on the posttranslational processing of 
bovine PrP in N2a cells with that in BHK cells and the fact that the 
posttranslational processing of boPrP differs between these cell culture systems is 
an important new observation. The cleavage pattern of PrP observed in healthy 
bovine brain, representing the normal in vivo cellular processing, contains large 
amounts of C1 which is also the case in boPrP-expressing BHK cells but not in 
boPrP-expressing N2a cells. Furthermore, a cleavage in the extreme C-terminus 
resulted in shedding of boPrP from the cell surface of BHK cells. The high level of 
expression enabled a short pulse-labelling approach that made it possible to very 
precisely determine the time-course for the C1 and extreme C-terminal proteolytic 
clevages. In N2a cells, the majority of boPrP was subjected to a more complete 
degradation process, and only trace amounts of full length boPrP was shed into 
cell culture medium in a process which also indicated a release by proteolytic 
cleavage.  
 
The results in this paper revealed that shedding of PrP into the extracellular 
medium, represent an important step in the normal posttranslational processing of 
boPrP. The observation that this shedding is protease-mediated is interesting as 
many GPI-achored proteins exert their functional role when proteolytically   35
released from its GPI-anchor (Kahl et al., 2000; Tsuji, Kaji & Nagasawa, 1994). 
Thus, this observation can be important with regard to functional aspects of PrP
C. 
 
Paper II: Exosome- and Protease-mediated Shedding of the Bovine Prion 
Protein is Unaffected by Deletion of the C1 Cleavage Site 
The constitutive proteolytic shedding is an important posttranslational processing 
event in the biosynthesis of PrP. Its importance for functional aspects of PrP
C and 
its role in prion pathogenesis is unknown. This motivated us to study the cell 
surface shedding in detail. Interestingly, during the course of these studies a 
mechanism of release distinct from the protease-mediated was discovered. Further 
analyses identified this mechanism as being exosome-mediated. In addition, the 
importance of the C1 cleavage for these different mechanisms of release was 
investigated. 
 
In order to investigate the influence of the C1 cleavage on the shedding of boPrP 
from the cell, a deletion mutant of the cleavage site was studied. Although the 
cleavage was partially hindered, the export of PrP to the medium was unaffected. 
Two distinct released PrP populations could be found in the cell medium. The 
major fraction was released by proteolysis near the GPI anchor. The other, minor 
fraction, was released in association with exosomes as separated out by differential 
ultracentrifugation and further characterized by Western immunoblotting with 
exosome-specific markers, phospholipase assays, and electron microscopic 
analysis. Less then 1% of the released boPrP was exported in association with 
exosomes. When the protease-mediated shedding was inhibited by the use of a 
zinc metalloprotease inhibitor, exosome-mediated shedding of boPrP was not 
affected, suggesting separate pathways and a constitutive shedding of exosome-
associated boPrP. Indications of a low level of phospholipase-mediated shedding 
was observed, probably due to phospholipase activities in the fetal calf serum 
present in the cell culture medium.  
 
Taken together, the results presented in this study indicate that a deletion of the 
C1 cleavage site inhibits, albeit only partially, the cleavage of full length boPrP 
into C1. However, the slowed rate of C1 cleavage results in profound changes in 
the composition of boPrP shed from the cell into the extracellular medium. The 
finding that boPrP in addition to a protease-mediated release also is released in 
association with exosomes, provide important information in relation to functional 
aspects of PrP
C and possible roles in pathogenesis.  
 
Paper III: Characterization of Proteinase K-resistant N- and C-terminally 
Truncated PrP in Nor98 Atypical Scrapie  
In this paper, a newly discovered prion disease of sheep, Nor98, was characterized 
with regard to its molecular properties. Some features of the PK-resistant PrP 
fragments in Nor98 resembled those of PrP fragments associated with the human 
prion disease Gerstmann-Sträussler-Scheinker syndrome. 
 
An increasing number of scrapie cases with atypical characteristics, designated 
Nor98, have recently been recognized in many countries in Europe. In this paper,  36
the proteinase K (PK)-resistant prion protein (PrP) fragments from two Swedish 
cases of Nor98 atypical scrapie was characterized. The prominent, fast-migrating 
band in the distinct Nor98 Western immunoblot electrophoretic profile was 
determined to be of 7 kDa in size and was accordingly designated Nor98-PrP7. 
The antigenic composition of Nor98-PrP7, as assayed by a panel of anti-PrP 
antibodies, revealed that this fragment comprised a mid-region of PrP from around 
aa 85 to 148. N- and C-terminally truncated fragments spanning the mid-region of 
PrP have previously only been observed in the genetic prion disorder Gerstmann-
Sträussler-Scheinker syndrome. It is shown in this paper that the long-term PK 
resistance of Nor98-PrP7 is reduced compared with that of PrP-res in classical 
scrapie. Enzymatic deglycosylation did not change the distinct electrophoretic 
profile of Nor98-PrP7. A previously unidentified, PK-resistant, C-terminal PrP 
fragment of around 24 kDa was detected and its PK resistance was investigated. 
After deglycosylation, this fragment migrated as a 14 kDa polypeptide and was 
designated PrP-CTF14. Antigenic determination and the size of 14 kDa suggested 
a fragment spanning approximately aa 120-233. The existence of two PK-resistant 
PrP fragments, Nor98-PrP7 and PrP-CTF14, that share an overlapping region 
suggests that at least two distinct PrP conformers with different PK-resistant cores 
are present in brain extracts from Nor98-affected sheep. The structural gene of PrP 
in three Nor98-affected sheep was analysed, but no mutations were found that 
could be correlated to the aberrant PK-resistant profile observed. 
 
In conclusion, this study shows that the PK-resistant PrP fragments present in 
Nor98-affected sheep display striking similarities to those found in individuals 
affected by the human prion disorder Gerstmann-Sträussler-Scheinker syndrome 
(GSS). Interestingly, GSS is always associated with aa substitutions in the PrP. 
Differently, no changes in the PrP of Nor98-affected sheep have been found. The 
findings presented in this paper together with observations of a distinct 
epidemiology, suggest that Nor98 could be the result of an age-related 
spontaneous conversion of PrP
C into PrP
Nor98 similar to that proposed for sCJD and 
sFI. 
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Concluding remarks and future perspectives 
In order to elucidate the underlying molecular basis of prion diseases, continued 
thorough studies of the normal cellular prion protein must be conducted. If the 
function(s) of PrP
C is clarified, most probably it will result in new approaches for 
therapeutic interventions and new targets for pharmacological treatment strategies.  
 
The present investigations reveal that the posttranslational processing of boPrP 
differ significantly between cell lines, emphasizing the importance of knowledge 
of the cell culture model used for studies of PrP. The findings further underscores 
the significance of differences in specific protease activities in different cell lines. 
The knowledge that cleavage into C1 occurs in vivo in all species studied to date is 
crucial for the choice of cell culture models and antibodies for detection of PrP and 
fragments thereof. Against the background of this, these studies demonstrate 
conclusively that deglycosylation is a prerequisite for any type of studies of the 
cell biology of PrP
C and PrP
Sc and that it must be used in combination with 
different PrP-antibodies to detect full length as well as both N-terminal and C-
terminal fragments of PrP. Of particular note is mAb 3F4, the epitope of which 
covers the C1 cleavage site and is thus destroyed upon posttranslational cleavage 
of full length PrP into C1. This epitope is naturally present in human and hamster 
PrP, and mAb 3F4 has an absolute requirement for the sequence M109K110H111M112 
(huPrP numbering) (Kascsak et al., 1987). As this epitope is not present in mouse 
PrP (moPrP), insertion of a “3F4-tag” of this sort into moPrPs expressed 
exogenously by transfection is frequently used to be able to separate it from 
endogenous moPrP present in cell lines of murine origin. A better choice in this 
regard is to insert the epitope of mAb L42, which has a requirement for W at 
position 145 (huPrP numbering) (Vorberg et al., 1999). In addition to 
identification of exogenously expressed moPrP this “L42-tag” enables detection of 
both full length and C1 PrP. 
 
The mouse neuroblastoma cell line N2a is the cell line of choice for studies of 
mouse-adapted scrapie and also for studies of PrP
C from various species. However, 
in light of our findings that boPrP is efficiently degraded and does not undergo the 
C1 cleavage in N2a cells, caution should be taken when performing studies of the 
cellular processing of PrPs in this cell line.  
 
Interesting future investigations include creating mutants of PrP that affects the 
proteolytic shedding and the C1 cleavage and study the role of these processing 
events for PrP
C function and prion propagation. The separation of boPrP released 
by the two distinct mechanisms into a pellet and a supernantant fraction, 
respectively, could prove to be a useful tool for characterisation of PrP populations 
associated with infectivity. Moreover, since exosomes from infected cells have 
been shown to be infectious, it would be interesting to investigate if also the PrP 
population in the 100,000 x g pellet from medium conditioned with prion-infected 
cells, contain any infectivity. If that is not the case, a therapeutic approach to treat 
prion infection could be to increase the proteolytic shedding in order to reduce the 
amount of PrP
C available for subsequent conversion into PrP
Sc and release from  38
the cell via exosomes. In this regard, identification of the proteases responsible for 
the proteolytic shedding could be of great interest. Construction of mice deficient 
for proteases involved in C1 cleavage and/or shedding could provide important 
insights to the function of PrP
C and the role of these processing events in prion 
pathogenesis. 
 
The characterization of the Nor98 prion presented in this thesis reveal striking 
similarities with the GSS prion as discussed above. As both Nor98 and GSS prions 
display relatively low PK-resistance it would be interesting to investigate if 
anomalous association with membranes in the cell could explain the unusual 
properties rather than a typical aggregation process, as transmembrane forms of 
PrP have been identified in models of GSS (DeArmond & Prusiner, 2003; Harris, 
2003; Hegde et al., 1998; Hegde et al., 1999; Kim, Rahbar & Hegde, 2001; 
Stewart & Harris, 2001). In this regard it would be exceedingly useful to set up a 
cell culture model infected with Nor98 to study the molecular basis of this disease. 
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